Particle Sciences senior team is comprised of seasoned industry leaders. They bring their decades of commercial experience to bear on producing practical and creative solutions to your drug development challenges.
Our proven management team includes:
Dr. Mitchnick founded Particle Sciences in 1991 and has been its CEO since that time. Prior that he was a practicing physician in New York and in a number of developing countries. In addition to his role as CEO, Dr. Mitchnick has been extensively involved in global health endeavors. He is an active member of the life sciences community, a consultant for several private equity firms and has served as a Director for multiple therapeutic and diagnostic companies. Dr. Mitchnick holds over 20 patents related to drug delivery, diagnostics and physiologic monitoring. He earned a B.Sc. in Animal Sciences from Purdue University and his MD from Georgetown University Medical School. He trained in Pediatrics at The New York hospital, Cornell Medical Center and completed the OPM program at Harvard Business School.
Dr. Lee is responsible for product development. Before joining Particle Sciences, Rob held senior management positions at Novavax, Inc., Lyotropic Therapeutics, Inc., and Imcor Pharmaceutical Co. He holds BSs in Biology and Chemistry from the University of Washington and a PhD in Physical Bioorganic Chemistry from the University of California, Santa Barbara. Rob has published articles in numerous peer-reviewed journals and three book chapters plus holds 11 issued patents and 14 provisional or PCT patent applications. He has over 23 years of experience in pharmaceutical research and development of both therapeutic drugs and diagnostic imaging agents. Rob maintains strong academic ties, including an appointment as Adjunct Associate Professor of Pharmaceutical Chemistry at the University of Kansas in 1992, and serving as a reviewer for both the International Journal of Pharmaceutics and Journal of Pharmaceutical Sciences.
Dr. Frank has been leading Project Management and Client Relations at Particle Sciences since 2007. His scientific background is in Organic Chemistry, with over 20 years experience leading Discovery Chemistry and Project Management efforts in both large publicly traded companies and small biotechnology firms. Prior to joining Particle Sciences, Bruce was Director of Discovery Chemistry at FMC Corporation (Princeton, NJ) where he directed over 40 medicinal and analytical chemistry scientists on site and overseas. Previous positions include Director of Chemistry at Kimeragen/Valigen (Newtown, PA), Senior Scientist at Hybridon (Cambridge, MA) and Post-doctoral Scientist at DuPont-Merck Pharmaceutical Co. (Wilmington, DE). He received his PhD in Organic Chemistry from the University of Maryland and a BA in Chemistry from Temple University. Bruce has over 35 publications, presentations and patent disclosures to his credit.
Dr. Tiwari joined Particle Sciences in 2013 and is responsible for leading formulation and process development. He holds a PhD in Pharmaceutical Sciences from St. John’s University and joins Particle Sciences following more than 18 years’ of experience in pharmaceutical development roles. Most recently, he served as Director, Pharmaceutical Development at Agennix Inc. and prior to that he held senior positions at Baxter and Bayer. His areas of expertise include formulation development, clinical trial materials manufacturing, and commercial scale manufacturing of various dosage forms (parenteral, oral, inhalation, and topical). He has been integral to over 20 regulatory submissions worldwide and seven marketed drug products. Deepak has numerous publications, presentations and patent applications to his credit.
Andrew Loxley, PhD is Director of New Technologies at Particles Sciences Inc., one of three formulation groups at the company. Andrew's group focusses on drug delivery projects ranging from nanoparticles to combination products - drug eluting devices. Prior to joining Particles Sciences in 2005, Andrew led development efforts in next-generation lithium ion batteries at A123 Systems Inc, electrophoretic displays at EINK Corp., and emulsion polymers at Synthomer Ltd. He earned his BSc in chemistry and polymer science from the University of Sussex, UK, and his PhD in physical chemistry focusing on microencapsulation from the University of Bristol, UK. Dr Loxley is the inventor on more than 40 patents, author of two book chapters and several peer reviewed and trade-journal articles.
Mr. Gwozdz joined Particle Sciences in 1994 to establish and run the formulations laboratory. Prior to that, he spent 13 years working in the specialty ink industry. He is now responsible for managing the Formulation Services group, encompassing multiple delivery vehicle formats, such as topical, vaginal, buccal, nasal, and injectables, as well as techniques related to fine particle dispersion, suspension, and size reduction. He has developed and scaled a number of commercialized formulations as well as many to support preclinical and clinical research. Mr. Gwozdz holds patents relating to drug delivery, as well as encapsulation and particulate surface modification technologies. He earned his Bachelor's of Science in Chemistry from the University of Pittsburgh.
Laurie Goldman joined Particle Sciences in 1997 as Analytic and Quality Manager. Building on a solid quality control and quality assurance framework from previous experience in the electronic chemicals, mining, and inks/coatings industries, she established and grew the state-of-the-art analytical laboratory at Particle Sciences. She has co-authored numerous technical publications. She holds a B.S. in Chemistry from Muhlenberg College and has been certified in statistical process control, quality engineering, and quality auditing.
Judith Cohen joined Particle Sciences in 2013 as Associate Director, Quality Assurance. Prior to joining Particle Sciences, Judith held leadership roles for over 22 years at Johnson & Johnson within the Pharmaceutical and Medical Device Sectors. She has extensive experience developing and implementing quality systems to support the manufacture and analytical characterization of clinical trial materials and commercial product. Judith has been integral in the preparation of Chemistry & Manufacturing Control sections for regulatory submissions worldwide for both pharmaceutical and drug/device combination products leading to the commercialization of over 20 products. Judith earned her Bachelor of Science in Chemistry from the University of Delaware and is a Fellow of the American Chemical Society.